| Patent Number |
Title Of Patent |
Date Issued |
| 7595299 |
Peptides as NS3-serine protease inhibitors of hepatitis C virus |
September 29, 2009 |
| The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them t |
| 7244721 |
Peptides as NS3-serine protease inhibitors of hepatitis C virus |
July 17, 2007 |
| The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat |
| 7169760 |
Peptides as NS3-serine protease inhibitors of hepatitis C virus |
January 30, 2007 |
| The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them t |
| 7115578 |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients hav |
October 3, 2006 |
| Ribavirin derivatives represented by the formula V, pharmaceutical compositions containing them as well as the use of the ribavirin derivatives represented by the formula V for the preparation of a medicament for the treatment of susceptible viral infections, for example, chronic hep |
| 7012066 |
Peptides as NS3-serine protease inhibitors of hepatitis C virus |
March 14, 2006 |
| The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat |
| 6924270 |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients hav |
August 2, 2005 |
| Ribavirin derivatives represented by the formula II, pharmaceutical compositions containing them as well as methods of using the ribavirin derivatives represented by the formula II for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administ |
| 6911428 |
Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus |
June 28, 2005 |
| The present invention is directed to certain diaryl amide compounds as NS3-Serine protease inhibitors of hepatitis C virus. A particularly preferred compound is of the formula: ##STR1## |
| 6894072 |
Compounds as NS3-serine protease inhibitors of hepatitis C virus |
May 17, 2005 |
| The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat |
| 6800434 |
Peptides as NS3-serine protease inhibitors of hepatitis C virus |
October 5, 2004 |
| The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to |
| 6673775 |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients hav |
January 6, 2004 |
| Ribavirin derivatives represented by formula I ##STR1##wherein at least one of R.sup.2, R.sup.3 or R.sup.5 is a straight or branched chain polyalkylene oxide polymer conjugate, and pharmaceutical compositions containing them as well as their use to treat patients having susceptible v |
| 6403564 |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients hav |
June 11, 2002 |
| A method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin derivative of formula I and a therapeutically effective amount of interferon-alpha for a time period |
| 6277830 |
5'-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
August 21, 2001 |
| 5'-Amino acid esters of ribavirin represented by formula I: ##STR1##wherein R is CH.sub.3 CH(NH.sub.2)--CO--, CH.sub.3 CH.sub.2 (CH.sub.3)CHCH(NH.sub.2)--CO--orH.sub.2 N(CH.sub.2).sub.4 CH(NH.sub.2)--CO--; preferably R is ##STR2##or a pharmaceutically acceptable salt thereof, e.g., trifl |
| 5925648 |
Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
July 20, 1999 |
| Novel tricyclic N-cyanoimine compounds and pharmaceutical compositions of formula (1.0) ##STR1## or a pharmaceutically acceptable salt or solvate thereof, wherein a, b, c, d, R.sup.1 -R.sup.8, X and Z are defined herein. Such compounds are inhibitors of the enzyme, farnesyl prote |
| 5883097 |
Soluble azole antifungal salt |
March 16, 1999 |
| The lactic acid[CH.sub.3 CH(OH)CO.sub.2 H] addition salt of the compound of formula I ##STR1## wherein the molar ratio of lactic acid, preferably L-lactic acid, to the compound of formula I is preferably about 1:1, pharmaceutical compositions of the lactic acid addition salt in a |
| 5714490 |
Tetrahydrofuran antifungals |
February 3, 1998 |
| A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two amino acid ester groups |
| 5710154 |
Tetrahydrofuran antifungals |
January 20, 1998 |
| A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two groups convertible in vi |
| 5703236 |
Tetrahydrofuran antifungals |
December 30, 1997 |
| A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two hydroxy moieties, an eth |
| 5703079 |
Tetrahydrofuran antifungals |
December 30, 1997 |
| A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two polyetyher ester groups |
| 5698557 |
Hydroxy-substituted antifungals |
December 16, 1997 |
| A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two hydroxy moieties, an eth |
| 5693626 |
Tetrahydrofuran antifungals |
December 2, 1997 |
| A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two phosphate ester groups ( |
| 5661151 |
Tetrahydrofuran antifungals |
August 26, 1997 |
| A compound represented by the formula I ##STR1## wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R.sub.1 is a straight or branched chain (C.sub.3 to C.sub.8) alkyl group substituted by one or two hydroxy moieties, an eth |
| 5403937 |
Process for preparing intermediates for the synthesis of antifungal agents |
April 4, 1995 |
| Disclosed is a process for preparing chiral compounds of the formula (I) ##STR1## wherein: X.sup.1 and X.sup.2 are independently F or Cl; and E is --SO.sub.2 R.sup.2, wherein R.sup.2 is C.sub.1 -C.sub.6 alkyl, --C.sub.6 H.sub.4 CH.sub.3 or --CF.sub.3 ; its enantiomer and racemates th |
| 4877801 |
1-Aryl-1-(1H-azol-1-ylalkyl)-1,3-dihydroisobenzofurans, related derivatives and pharmaceutical c |
October 31, 1989 |
| Novel compounds including 1-aryl-1-(1H-imidazol-1-ylmethyl)-1,3-dihydroisobenzofurans such as 1-(4-chlorophenyl)-1-(1H-imidazol-1-ylmethyl)-1,3-dihydroisobenzofuran, and 1-aryl-1-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dihydroisobenzofurans are disclosed. The corresponding benzo[c]thiophen |
| 4737508 |
1-aryl-1-(1H-azol-1-ylalkyl)-1,3-dihydroisobenzofurans, related derivatives and pharmaceutical c |
April 12, 1988 |
| Novel compounds including 1-aryl-1-(1H-imidazol-1-ylmethyl)-1,3-dihydroisobenzofurans such as 1-(4-chlorophenyl)-1-(1H-imidazol-1-ylmethyl)-1,3-dihydroisobenzofuran, and 1-aryl-1-(1H-1,2,4-trizazol-1-ylmethyl)-1,3-dihydroisobenzofurans are disclosed. The corresponding benzo[c]thiopen |
| 4507294 |
Imidazo[1,2-a]pyrazines |
March 26, 1985 |
| There are disclosed herein certain substituted imidazo[1,2-a]pyrazine compounds which are useful in the treatment of peptic ulcer diseases. |
| 4464372 |
Imidazo[1,2-b]pyridazines |
August 7, 1984 |
| There are disclosed herein certain substituted imidazo[1,2-b]pyridazine compounds which are useful in the treatment of peptic ulcer diseases. |
| 4409226 |
Imidazo[1,5-a]pyridines |
October 11, 1983 |
| The invention relates to imidazo[1,5-a]pyridine derivatives which are useful in the treatment of peptic ulcer diseases. |
| 4361567 |
Treatment of peptic ulcer disease |
November 30, 1982 |
| Disclosed herein are certain imidazo[1,5-a]pyridines, and pharmaceutical compositions containing them as the active ingredient for treatment and promotion of healing of peptic ulcer disease by virtue of their antisecretory and cytoprotective properties. |
| 4358454 |
1,3,4-Triazolo[1,5-a]pyridines |
November 9, 1982 |
| There are disclosed herein certain 1,3,4-triazolo[1,5-a]pyridine compounds which are useful in the treatment of peptic ulcer diseases. |
| 4358453 |
1,2,4-Triazolo[4,3-a]pyridines |
November 9, 1982 |
| There are disclosed herein certain 1,2,4-triazolo-[4,3-a]pyridine compounds which are useful in the treatment of peptic ulcer diseases. |
